Ubs Oconnor LLC Fusion Pharmaceuticals Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.48 - $9.65 $152,423 - $593,098	-61,461 Reduced 22.38%	213,107 $2.05 Million
Q2 2023 Aug 14, 2023	BUY	$3.47 - $5.33 $952,750 - $1.46 Million	274,568 New	274,568 $1.28 Billion
Q1 2023 May 15, 2023	BUY	$3.03 - $5.13 $156,120 - $264,323	51,525 Added 27.05%	242,026 $912,000
Q4 2022 Feb 14, 2023	BUY	$2.1 - $3.34 $363,751 - $578,538	173,215 Added 1002.05%	190,501 $0
Q3 2022 Nov 14, 2022	BUY	$2.0 - $3.56 $34,572 - $61,538	17,286 New	17,286 $52 Million

93K

1.4K

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.